Siu Choy - United Laboratories Executive Director
| ULIHFDelisted Stock | USD 1.09 0.00 0.00% |
Director
Ms. Choy Siu Chit is the Executive Director of The United Laboratories International Holdings Limited. Ms. Choy joined the Group in 1990. She handled the Drug Master File submission relating to the Groups amoxicillin bulk medicine with the FDA pursuant to which the Group became the holder of Drug Master File Type II relating to its amoxicillin bulk medicine in 2001. Ms. Choy also holds directorship in certain subsidiaries of the Company. She passed the Private Equity Investment Fund Advanced Class organized by the Beijing University with distinction in 2010. Ms. Choy is a director of Mighty Brokerage Limited, which principally provides brokerage and securities trading services in Hong Kong. since 2013.
| Age | 50 |
| Tenure | 11 years |
| Phone | 852 2687 1033 |
| Web | https://www.tul.com.cn |
United Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0539 % which means that it generated a profit of $0.0539 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1056 %, meaning that it generated $0.1056 on every $100 dollars invested by stockholders. United Laboratories' management efficiency ratios could be used to measure how well United Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.The United Laboratories has accumulated 221.21 M in total debt with debt to equity ratio (D/E) of 0.22, which may suggest the company is not taking enough advantage from borrowing. The United Laboratories has a current ratio of 1.57, which is within standard range for the sector. Debt can assist United Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, United Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like The United Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for United to invest in growth at high rates of return. When we think about United Laboratories' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | DIRECTOR Age | ||
| Emily Gacka | The Gap, | N/A | |
| Inge Vanwittenbergh | Nyxoah | N/A | |
| Christopher Genualdi | NETGEAR | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0539 |
The United Laboratories Leadership Team
Elected by the shareholders, the United Laboratories' board of directors comprises two types of representatives: United Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of United. The board's role is to monitor United Laboratories' management team and ensure that shareholders' interests are well served. United Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, United Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karen Yang, Ma Relations | ||
| Hoi Tsoi, Executive Chairman of the Board | ||
| Xian Zou, Vice President Executive Director | ||
| Siu Choy, Executive Director | ||
| FCPA CPA, CFO Chairman | ||
| Su Zhu, Vice President Executive Director | ||
| Shou Wu, Head - Production Plant, Zhongshan | ||
| Yu Fang, Vice President Executive Director |
United Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is United Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0539 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 850.36 M | |||
| Shares Outstanding | 1.82 B | |||
| Shares Owned By Insiders | 50.35 % | |||
| Shares Owned By Institutions | 8.56 % | |||
| Price To Earning | 8.47 X | |||
| Price To Book | 0.67 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in United Pink Sheet
If you are still planning to invest in The United Laboratories check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the United Laboratories' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |